Total and H-specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration.

Konstantinidou SK, Argyrakopoulou G, Simati S, Stefanakis K, Kokkinos A, Analitis A, Mantzoros CS

Diabetes, obesity & metabolism17 May 2024Cited by 4 (Europe PMC)

PMID38757729DOI10.1111/dom.15642PepBankPUB-38757729

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

3 results from studies that gave the peptide. 3 results from people.

01HumanNon-randomized trialMechanism
In adults with overweight or obesity, postprandial total GDF-15 AUC and incremental AUC did not differ significantly between liraglutide and naltrexone/bupropion groups.
In plain wordsIn adults with overweight or obesity, total GDF-15 after a meal did not differ significantly between liraglutide and naltrexone/bupropion groups.
Peptide
Liraglutide
Outcome
No significant changePostprandial total GDF-15 AUC, liraglutide versus naltrexone/bupropion
Study
n = 42
Comparator
Naltrexone/bupropion
Outcome group
Adipokines · Metabolic and weight
Studied dose
3 mg · 3 and 6 monthsAs given in this study (human).
Source sentences
Summary
No significant differences between treatment groups in postprandial area under the curve (AUC) or incremental AUC values were found at baseline or in the follow-up months with regard to total and H-specific GDF-15 levels.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 42 individuals with overweight or obesity without type 1 or type 2 diabetes mellitus were enrolled.
Summary · context
The participants received either Lira 3 mg or N/B 32/360 mg, along with diet and exercise, according to comorbidities, cost and method of administration.
Report a problemFND-3875772905
02HumanNon-randomized trialMechanism
In adults with overweight or obesity, postprandial H-specific GDF-15 AUC and incremental AUC did not differ significantly between liraglutide and naltrexone/bupropion groups.
In plain wordsIn adults with overweight or obesity, H-specific GDF-15 after a meal did not differ significantly between liraglutide and naltrexone/bupropion groups.
Peptide
Liraglutide
Outcome
No significant changePostprandial H-specific GDF-15 AUC, liraglutide versus naltrexone/bupropion
Study
n = 42
Comparator
Naltrexone/bupropion
Outcome group
Adipokines · Metabolic and weight
Studied dose
3 mg · 3 and 6 monthsAs given in this study (human).
Source sentences
Summary
No significant differences between treatment groups in postprandial area under the curve (AUC) or incremental AUC values were found at baseline or in the follow-up months with regard to total and H-specific GDF-15 levels.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 42 individuals with overweight or obesity without type 1 or type 2 diabetes mellitus were enrolled.
Summary · context
The participants received either Lira 3 mg or N/B 32/360 mg, along with diet and exercise, according to comorbidities, cost and method of administration.
Report a problemFND-3875772906
03HumanNon-randomized trialMechanism
In adults with overweight or obesity, the subgroup analysis of liraglutide versus naltrexone/bupropion found no statistically significant GDF-15 response to the meal.
In plain wordsIn adults with overweight or obesity, a blood marker (GDF-15) showed no significant difference between liraglutide and naltrexone/bupropion groups after a meal.
Peptide
Liraglutide
Outcome
No significant changeGDF-15 change during mixed meal, liraglutide subgroup
Study
n: not reported in source
Comparator
Naltrexone/bupropion
Outcome group
Adipokines · Metabolic and weight
Studied dose
3 mg · 3 and 6 monthsAs given in this study (human).
Source sentences
Summary
No statistical significance was found when participants were examined by subgroup (Lira vs. N/B).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 42 individuals with overweight or obesity without type 1 or type 2 diabetes mellitus were enrolled.
Summary · context
The participants received either Lira 3 mg or N/B 32/360 mg, along with diet and exercise, according to comorbidities, cost and method of administration.
Report a problemFND-3875772904

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

04HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In adults with overweight or obesity given liraglutide or naltrexone/bupropion, pooled weight fell by 9.29 kg at month 3 and 11.52 kg at month 6.
In plain wordsIn adults with overweight or obesity given one of two weight-loss drugs, weight fell over 6 months in the two groups combined.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n = 42
Outcome group
Body weight · Metabolic and weight
Measurements
Weight reduction
9.29 kg
Month 3, all participants
Weight reduction
11.52 kg
Month 6, all participants
Source sentences
Summary
Overall, participants' weight was reduced by 9.29 ± 5.34 kg at Month 3 and 11.52 ± 7.52 kg at Month 6.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 42 individuals with overweight or obesity without type 1 or type 2 diabetes mellitus were enrolled.
Summary · context
The participants received either Lira 3 mg or N/B 32/360 mg, along with diet and exercise, according to comorbidities, cost and method of administration.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3875772901
05HumanNot a test of Liraglutide aloneNon-randomized trialMechanism
In adults given liraglutide or naltrexone/bupropion, total GDF-15 did not change significantly during a mixed meal at baseline, 3 or 6 months, in all participants pooled.
In plain wordsIn adults given one of two weight-loss drugs, a blood marker (GDF-15) did not change after a meal, with both groups combined.
Peptide
Liraglutide
Outcome
No significant changeTotal GDF-15 change during mixed meal, all participants
Study
n = 42
Outcome group
Adipokines · Metabolic and weight
Source sentences
Summary
Total and H-specific GDF-15 levels did not show significant changes during the mixed meal compared to values before the meal when all participants were examined at baseline, and at 3 and 6 month follow-ups.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 42 individuals with overweight or obesity without type 1 or type 2 diabetes mellitus were enrolled.
Summary · context
The participants received either Lira 3 mg or N/B 32/360 mg, along with diet and exercise, according to comorbidities, cost and method of administration.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3875772902
06HumanNot a test of Liraglutide aloneNon-randomized trialMechanism
In adults given liraglutide or naltrexone/bupropion, H-specific GDF-15 did not change significantly during a mixed meal at baseline, 3 or 6 months, in all participants pooled.
In plain wordsIn adults given one of two weight-loss drugs, a form of the blood marker GDF-15 did not change after a meal, with both groups combined.
Peptide
Liraglutide
Outcome
No significant changeH-specific GDF-15 change during mixed meal, all participants
Study
n = 42
Outcome group
Adipokines · Metabolic and weight
Source sentences
Summary
Total and H-specific GDF-15 levels did not show significant changes during the mixed meal compared to values before the meal when all participants were examined at baseline, and at 3 and 6 month follow-ups.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 42 individuals with overweight or obesity without type 1 or type 2 diabetes mellitus were enrolled.
Summary · context
The participants received either Lira 3 mg or N/B 32/360 mg, along with diet and exercise, according to comorbidities, cost and method of administration.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3875772903

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.